Galmed Pharmaceuticals Ltd. (GLMD) announced the grant of a European patent related to the use of a combination of Aramchol and Resmetirom for the treatment of NASH/MASH and liver fibrosis. The company said the patent was granted in France, Germany, Italy, the Netherlands and the United Kingdom and the approval of the patent in the United States and other countries is pending.
Galmed Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases.
Shares of Galmed Pharmaceuticals are up 40% in pre-market trade on Friday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.